Irritable Bowel Drugs From Salix, Actavis Await FDA Action In 2015
This article was originally published in The Pink Sheet Daily
Executive Summary
With new retreatment data in hand, Salix is again pursuing a supplemental claim for the antibacterial Xifaxan, while Actavis is seeking approval of eluxadoline, a new molecular entity with dual opioid receptor activity.
You may also be interested in...
Actavis Flexes Its Commercial Muscles Ahead Of Allergan Integration
Before adding Allergan into the mix – and taking on its name – Actavis wants to show investors that it has a solid foundation as a growth pharma with strong brands in GI, CNS and women’s health.
Valeant Reasons, Ackman Threatens In Latest Allergan Takeover Moves
Valeant and activist investing partner Bill Ackman took opposite approaches to reports that Allergan may be pursuing Salix buyout as a defensive move to block a takeover. Acquiring Salix could put the cost of Allergan out of Valeant and Ackamn’s reach.
Valeant Reasons, Ackman Threatens In Latest Allergan Takeover Moves
Valeant and activist investing partner Bill Ackman took opposite approaches to reports that Allergan may be pursuing Salix buyout as a defensive move to block a takeover. Acquiring Salix could put the cost of Allergan out of Valeant and Ackamn’s reach.